Four different hands putting puzzle pieces together.

Innovation Ecosystem

In 2021, Weill Cornell Medicine Enterprise Innovation was formed to support the innovation and entrepreneurship needs of Weill Cornell faculty and trainees and to be an accelerator of New York City as a growing biomedical hub. With a new centralized infrastructure, Enterprise Innovation is well equipped to provide end-to-end support to our internal and external stakeholders through the full innovation lifecycle from inception to commercialization. Enterprise Innovation also supports the Weill Cornell Medicine campus in Doha, Qatar (WCM-Q) seeking to build external research alliances with global partners and expand the WCM-Q research enterprise.

BioVenture eLab

The BioVenture eLab is the hub of entrepreneurial activities at Weill Cornell Medicine with the mission of growing a robust entrepreneurial and company creation ecosystem and providing access to necessary resources to build the next generation of leaders and successful companies in the life sciences.

Center for Technology Licensing at Weill Cornell Medicine

The Center for Technology Licensing (CTL) is Cornell University’s technology transfer office. CTL’s mission is to bring the University’s scientific discoveries, technological innovations and medical advances to the marketplace for societal benefit and to foster new venture creation and growth.

Weill Cornell Medicine in Qatar (WCM-Q)

Weill Cornell Medicine in Qatar (WCM-Q) is the first US medical school established outside the country. It is at the forefront of medical education, biomedical research and population health in the Middle East/North Africa (MENA) region.

Sanders Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI)

Tri-I TDI’s mission is to translate groundbreaking biological discoveries into novel small molecule or biologic therapeutics. It partners with Enterprise Innovation by providing industry-quality technical support for academic projects, making it possible for our researchers to rapidly develop and assess the utility of specific therapeutics in disease-relevant contexts.